CSIMarket
 


Genfit S a   (GNFT)
Other Ticker:  
 
 

GNFT's Operating Income Growth by Quarter and Year

Genfit S A 's Operating Income results by quarter and year




GNFT Operating Income (in millions $) FY 2022 FY 2021 FY 2020 FY 2019
IV Quarter December -30.56 35.63 -92.84 -64.77
III Quarter September 0.00 0.00 0.00 0.00
II Quarter June 0.00 0.00 0.00 0.00
I Quarter March 0.00 0.00 0.00 0.00
FY   -30.56 35.63 -92.84 -64.77



GNFT Operating Income fourth quarter 2022 Y/Y Growth Comment
Genfit S a in the fourth quarter 2022 recorded Operating Loss of $ -30.56 millions.

According to the results reported in the fourth quarter 2022, Genfit S A achieved the best Operating Income growth in Biotechnology & Pharmaceuticals industry. While Genfit S A ' s Operating Income no change of % ranks overall at the positon no. in the fourth quarter 2022.

Explain Operating Income growth


GNFT Operating Income ( Y/Y Growth %) 2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY   - - - -

Financial Statements
Genfit S A 's fourth quarter 2022 Operating Income $ -30.56 millions GNFT's Income Statement
Genfit S A 's fourth quarter 2021 Operating Income $ 35.63 millions Quarterly GNFT's Income Statement
New: More GNFT's historic Operating Income Growth >>


GNFT Operating Income (Quarter on Quarter Growth %)

2022
2021 2020 2019
IV Quarter December - - - -
III Quarter September - - - -
II Quarter June - - - -
I Quarter March - - - -
FY (Year on Year)   - - - -




Operating Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 
Operating Income fourth quarter 2022 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Y/Y Growth Statistics
High Average Low
0 % 0 % 0 %
 

Operating Income by Quarter for the Fiscal Years 2019, 2020, 2021, 2022

Genfit S A 's Q/Q Operating Income Growth


Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNFT's IV. Quarter Q/Q Operating Income Comment


Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #
Operating Income Q/Q Growth Statistics
High Average Low
0 % 0 % 0 %
 


GNFT's IV. Quarter Q/Q Operating Income Comment


Genfit S A 's 12 Months Operating Income Growth Year on Year


Operating Income TTM Growth

12 Months Ending
(Dec 31 2022)
12 Months Ending
0
12 Months Ending
0
12 Months Ending
0
12 Months Ending
(Dec 31 2021)
Cumulative Operating Income 12 Months Ending $ -30.56 $ 0.00 $ 0.00 $ 0.00 $ 35.63
Y / Y Operating Income Growth (TTM) - - - - -
Year on Year Operating Income Growth Overall Ranking # # # # #
Seqeuential Operating Income Change (TTM) - - - - -
Seq. Operating Income Growth (TTM) Overall Ranking # # # # #




Cumulative Operating Income growth Comment
Genfit S A realized trailing twelve months Operating Loss of $ -31 millions, in the Dec 31 2022, compare to Operating Income of $ 36 millions a year ago.

Genfit S a achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 

Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #
Cumulative Operating Income growth Comment
Genfit S A realized trailing twelve months Operating Loss of $ -31 millions, in the Dec 31 2022, compare to Operating Income of $ 36 millions a year ago.

Genfit S a achieved highest trailing twelve month year on year Operating Income growth. While overall Operating Income growth ranking, remained unchanged compare to the previous quarter at no. .

Operating Income TTM Q/Q Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #
Healthcare Sector #
Overall #

Operating Income TTM Y/Y Growth Statistics
High Average Low
0 %
0 %
0 %
 


Operating Income TTM Q/Q Growth Company Ranking
Within: No.
Industry #
Sector #
S&P 500 #




Other Operating Income Growth
Biotechnology & Pharmaceuticals Industry Operating Income Growth Trends and Statistics
Healthcare Sector Operating Income Growth Statistics
Operating Income Growth Trends for overall market
GNFT's Operating Income Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Operating Income Growth
Lowest Ranking Operating Income Growth
Operating Income Growth for GNFT's Competitors
Operating Income Growth for Genfit S A 's Suppliers
Operating Income Growth for GNFT's Customers

You may also want to know
GNFT's Annual Growth Rates GNFT's Profitability Ratios GNFT's Asset Turnover Ratio GNFT's Dividend Growth
GNFT's Roe GNFT's Valuation Ratios GNFT's Financial Strength Ratios GNFT's Dividend Payout Ratio
GNFT's Roa GNFT's Inventory Turnover Ratio GNFT's Growth Rates GNFT's Dividend Comparisons



Companies with similar Operating Income no change for the quarter ending Dec 31 2022 within Healthcare SectorY/Y Change %Operating Income for the quarter ending Dec 31 2022
Stryker Corp-0.61%$ -0.611 millions
National Healthcare Corp-1.05%$ -1.050 millions
Utah Medical Products Inc-1.15%$ -1.150 millions
Vaso Corporation-1.36%$ -1.365 millions
Mesoblast Ltd-3.09%$ -3.088 millions
Amgen Inc -3.21%$ -3.212 millions
Amedisys Inc -3.99%$ -3.989 millions
Eli Lilly And Company-4.21%$ -4.214 millions
Ligand Pharmaceuticals Incorporated-4.39%$ -4.389 millions
National Research Corporation-4.91%$ -4.910 millions
Charles River Laboratories International inc -5.21%$ -5.206 millions
Steris Plc-5.98%$ -5.977 millions
Baxter International Inc -7.83%$ -7.833 millions
Sotera Health Company-9.42%$ -9.421 millions
Polypid Ltd -9.87%$ -9.867 millions
Alpha Pro Tech Ltd -10.18%$ -10.178 millions
Qilian International Holding Group Limited-11.98%$ -11.978 millions
Zynex inc -12.74%$ -12.740 millions
Essa Pharma inc -14.14%$ -14.138 millions
Qiagen N v -15.65%$ -15.653 millions
Hca Healthcare Inc -15.73%$ -15.728 millions
Lemaitre Vascular Inc -16.07%$ -16.070 millions
Universal Health Services Inc -16.66%$ -16.664 millions
Teleflex Incorporated-17.08%$ -17.076 millions
Intuitive Surgical Inc -17.30%$ -17.296 millions
Surgery Partners Inc -17.94%$ -17.944 millions
Iqvia Holdings Inc -18.14%$ -18.143 millions
Fresenius Medical Care Ag-18.38%$ -18.385 millions
American Shared Hospital Services-18.40%$ -18.396 millions
Eton Pharmaceuticals Inc -19.18%$ -19.178 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com